Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce product...
Q3 2026
Aug 6, 2026
Q2 2026
May 7, 2026
Q1 2026
Feb 5, 2026
FY 2025
Nov 25, 2025
Q4 2025